U.S. pharma big copyright scrapped two experimental weight loss pills last year—a once-day by day tablet, lotiglipron, because of elevated liver enzymes in addition to a two times-day by day pill, danuglipron, resulting from robust Uncomfortable side effects—but CEO Albert Bourla has explained the company is set to “Engage in and win” withi